Compare Fidelity National Information Servcs Inc (FIS) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Moderna, Inc. — how do they compare? Fidelity National Information Servcs Inc trades at $34.5 (market cap $17.71B), while Moderna, Inc. trades at $197.19 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 4.4× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Moderna, Inc. for 59 Days on average.
| FIS | MRNA | |
|---|---|---|
Market Cap | $17.71B | $78.65B |
Volume | 9,047,825 | 37,373,437 |
Sector | Technology | Health |
52-Week High | $68.57 | $203.46 |
52-Week Low | $32.44 | $22.36 |
Typical Hold Time | 88 Days | 59 Days |
Enterprise Value | $38.22B | $74.80B |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $33.82, up 1.2% today, with a bearish technical signal and neutral oscillators. The stock shows attractive valuation with a P/E of 5.2 and P/S of 1.44, supported by a 27.65% net income margin and 22.33% ROE. Recent earnings beat expectations in Q1 and Q2 2026, and the company secured multiple core banking client wins, enhancing growth prospects.
Outlook is positive given low valuations and earnings momentum, but risks include high debt levels and inconsistent cash flow. Analyst consensus is bullish with a $47.54 price target, implying significant upside. Investors should monitor execution on revenue growth and debt management.
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
